The engines have fired up at last for MDX. ( BPRG ) At long last they are being recognised for the force they will become over the next two years. On the cusp of disclosing huge revenue-earning deals with Global pharmacists. These have been hinted at as being unrolled before the years end, but may be in the next days.You still have time to get in at a bargain-basement price before the SP takes off for real shortly.

i hear chocco has a ball sack :-)...what was that film called with Bob hoskins and the she man....?

scotinvestor...play nice...Al's is a dude

They don't do creme fraiche BigA, but they're big on Sauersahne, silly krauts (s'pose that'd be with a Schmiss of Apfeltorte).

Guess I haven't been on, gingernuts - can it wait until tomorrow for you to show me your sipps?

tfc???

sohlud??

me escape?......i love uk but unfortunately me and probably 10 million plus feel forced out by this gov and immigration policy.....globalisation doesnt work.....look at other western nations that use globalisation and they have same problems......i spoke to someone recently from south england up here on a weekend break and they were telling me bnp are getting lot of votes down that way.....bit late

as for shares, well is anyone or organisation doing well.....unless they struck oil....and even then theres no guarantee in sp....just look at tlw recently

bon nuit

With a drizzle of Schnapps? Good plan.

Anyway, back to BPRG - are there any good points here. This "we're going to get taken over by Big Pharma was doing the round in 03/04 over on ADVFN. It didn't happen and the thing went seriously into reverse. I really don't see anything that's going to make it any different this time around, especially at the prices usually bandied about. Have I missed something or what?

check out their website.....and recent operational review

i dont know about 2003 with pharma thing but i do think this is real with bid coming up. remember, company will be profit for this year coming up whereas in 2004 they were making 6 million loss when it was 160p.........the market can be very strange!

anyway al.....do some research and reading if u aint done so and then make a judgement.......

chocco no worries....will be around tomorrow night

Just found your mail thingie, blondie - didn't realise you'd missed me that much.
Wonderful :)

scottie - I've been keeping an eye on this lot all that time. As I said, I really can't see it any differently this time around. It's all Groundhog Day from where I'm sitting. I might be wrong, but what's the odds given past performance?

who knows al......we all make decisions in life whether good or bad...as i said before, i think next 2 years will transform as that will be giggest growth.....anyway as i said before just look at banks , housebuilders.....who'd have thought early 2007 that they would collapse

Morning all. You obviously had a late one Scotty I see you had some cruisers onlooks to me they were trying to get you the leading role in Debbie Does Dallas Id turn it down mate!
I thought today was going to be the day the teddy bears had their picniclooks like a baguette!

B J Muncaster - 30 Jul'08 - 08:04 - 93709 of 93714


Look, if you were considering a bid for MDX, then one way to build a stake without driving the price up would be to partner with other holders on the basis that when the deal is done the partner would either (a) receive the bid price for the loaned stock, or (b) have a pre-agreed stake in the new entity. By borrowing stock the borrower gets the voting rights without having to part with cash.

Something tells me Im into something good!

D & A Pharma went long with 4,138,945 shares (1.94%) yesterday.

D & A Pharam Capitalised at Euro 20M more like a company Meldex would takeover.

This certainly smacks of a profit warningright..where are all the 5p boys gone

;-))

Morning al..no chirpsee you were trying to soften up our PM. last night. You need to come round to our way of thinking.hes our Rottweiler!

funny how BJM knew RT was in paris yesterday ..... dont you think!!

d&a pharma are in paris

B J Muncaster - 30 Jul'08 - 06:32 - 1055 of 1056

daveperry,

Your point about the early filing of MDXs patent goes to the heart of the matter. What is not generally known, at least I dont think it is, is that we were developing films and filing patents long before almost any other company. In effect, weve laid an IP minefield that will prove difficult for others to walk through. More than 80 patents in 24 different families is one heck of a matrix to avoid.

Again, most people will not know that we started out life as Film Technology in the early 90s. Little cash, lots of ideas, but with a combination of pig-headed determination and a lot of support from early investors we managed to roll our knowledge base through several entities (always taking our investors with us) until we arrived at BioProgress in 1996.

Along the way we knew we had good ideas from a technical perspective, but we never really appreciated just how those ideas could impact global markets until big companies started nicking our products! One example: Larry Shattles and I set up a small booth at an exhibition in LA, proudly displaying a few bath oil beads encapsulated in XGel. We wandered off for a pint and on our return all our stock had gone. So we were left with just a booth and no stock for four days. Three years later, when in early discussions with Banner Pharmacaps, we were told by one of its executives that it was them that had run-off with our stock. Theyd been trying for years to find an alternative to gelatin to encapsulate drugs but couldnt crack the sealing process, and right there before their very eyes was problem solved by this two-bit outfit from the UK.

Right now I dont think we or anyone else can fully value our IP because until others step on a particular mine, and they will, we dont know how much in $$ terms theyll have to cough up.

I dont have any definite figures, but Id bet our total spend on patents thus far is more than 4 million. It was over 2 million when I left the Company in 2003. Quite a hidden asset yet to bear fruit, but it will.

One other point. Along the way our patent applications have been challenged at every stage by some big players. I think Im correct in saying that to date weve beaten every challenge.

I think its our strong, broad and deep IP base that really excites SM, you only have to look at the number of times hes talked about it in glowing terms. Just think about R&D people in other companies tasked with developing new film based products only to find they keep coming up against MDXs prior art, how frustrating and expensive can that be? With MDX, SM has most if not all of the cards to scoop the pot. He knows it and I know it, thats why Im invested here.

Interesting

Release issued 10th April 2007



Astorg Partners announces today the acquisition of the Groupe Ethypharm, one of the world leaders in the development and manufacturing of oral Drug Delivery Systems (DDS) for the pharmaceutical industry. Astorg holds 60% of Ethypharm. Gard Leduc and the management team will retain a significant equity interest of 29% in the company. Intermediate Capital Group and other investors will hold the remainder of the equity.


Ethypharm, one of the world leaders in the development and manufacturing of oral DDS, supplies both major pharmaceutical groups and generics players with high-end drugs that feature particular absorption technologies.
Drug Delivery Systems provide major benefits including improving the drug efficacy, enhancing patient compliance and comfort, extending the life cycle of existing drugs, and reducing the total cost of treatment.


Founded in 1977 in France by Gard Leduc, its current CEO, and Patrice Debregeas, Ethypharm is today a global company which employs 810 people in several production and/or R&D facilities based in France, Canada, China and India. Ethypharm presents a fully integrated business model, servicing client needs from R&D - with the development of patented drugs and technologies1 - to the registration and manufacturing of turnkey products, approved by the regulatory bodies and ready to be marketed. The companys portfolio currently comprises of approximately 50 products sold to more than 140 customers worldwide.

Alongside Astorg Partners, Ethypharm will seek to consolidate its world leadership in oral DDS through its strategic focus and dedication to innovation. It will also deploy an ambitious double strategy to improve its presence in North America, and to provide drug delivery solutions to the rising biotech drugs market.

Gard Leduc, co-founder, Chairman and CEO of Ethypharm, said: we develop, register and manufacture drugs in a better, more effective and economic way, all to the benefit of patients, healthcare professionals and regulatory bodies. We are proud to have brought Ethypharm, a French private company, to a global leading position. With the management team, we are delighted to partner with Astorg in Ethypharms capital: this will enable us to seize opportunities within our fast growing field of advanced pharmaceutical technologies.


Patrice Debregeas, co-founder of Ethypharm, said: I am very proud that Ethypharm has achieved a strong global presence in drug-delivery since its founding in 1977. This could not have happened without the terrific contribution of its employees, its customers and its management, and I wish to extend my heartfelt thanks to all who have made Ethypharm what it is today. I am confident that Astorg will help Ethypharm become even more successful in the future.

Thierry Timsit, Managing Partner at Astorg Partners added: we are very happy to be making this acquisition, alongside Ethypharms management and employees. Ethypharm, with its technological expertise and the outstanding quality of its staff, is ideally positioned to take advantage of the steady growth of the generic drugs market worldwide. We are looking forward to working with Ethypharms management team to expand the companys footprint both geographically and on the promising market of biotech therapies.

Astorg Partners

Astorg Partners is an independent fund management company, specializing in French mid-market buyouts. It currently manages over 1 billion of capital. Astorg Partners seeks to partner with successful and entrepreneurial management teams, to acquire businesses with attractive growth prospects, which Astorg will support through the provision of experienced governance and
adequate capital. Astorg enjoys a distinct entrepreneurial culture, a lean and local decision-making body enhancing its reactivity, and a true commitment to its partnering management teams.